Record Q3 revenue of $6.6 million ; growth of 89% over Q2 2018 and 790% over Q3 2017.

On October 18, 2018 , closed the acquisition of RVR Distribution ("RVR"), including five licensed distribution and manufacturing facilities across California , and several of the state's top independent branded products.

Distribution platform reached 486 licensed California dispensaries as of September 30, 2018 1 .

Advancing acquisition of 180 Smoke to provide California brand partners with rapid access to the Canadian market.

Closed the acquisition of premium Sonoma County craft cannabis producer, FloraCal ® Farms.

Continued to generate shareholder value through the monetization of non-core assets; +487% 2 return on invested capital.

Strong cash position of $75.3 million as of September 30, 2018 to continue executing our vision.

OTTAWA, Nov. 28, 2018 /CNW/ - Origin House Corp. d/b/a Origin House (CSE: OH) (OTCQX: ORHOF) ("Origin House" or the "Company"), a leading North American cannabis products and brands company, announced today the Company's financial results for the three and nine-month periods ended September 30, 2018. All figures are reported in Canadian dollars ($), unless otherwise indicated. Origin House's financial statements are prepared in accordance with International Financial Reporting Standards ("IFRS").

Marc Lustig, CEO of Origin House, commented, "Last quarter, we stated that after a substantial period of building a foundation, Origin House was at the beginning of a multi-period, sustainable acceleration in revenue growth. Year-to-date, we generated record revenue, completed four transformational acquisitions and are well-capitalized to continue growing. We expect to continue delivering strong revenue growth throughout Q4, 2019 and beyond, as RVR and 180 Smoke are integrated and as we further leverage our brand development and support platform. Our view is that the next 12 months are going to be critical in determining the winners in the cannabis space. Origin House is positioned as a premier operator in the largest and most dynamic cannabis market in the world and we believe we are just at the beginning of our growth curve. We expect this platform to become increasingly difficult to replicate and therefore increasingly valuable for our shareholders as our financial results accelerate, as well as for other operators in the cannabis space that need to be in California."

"One year ago, we unveiled our ambitions to the public. In that period, Origin House has already created a proven track record of identifying break-out brands, partnering with them and selling to customers in a competitive marketplace to drive mutual success," said Afzal Hasan, President and General Counsel of Origin House. "The financial results we generated in Q2 and Q3 are representative of just the initial framework of a model primed for growth. We have already shown some early success in supporting the growth of some of the largest independent brands in California, like Lowell's Smokes and King's Garden. Our growing suite of brand development and support solutions, including financing, allows us to structure innovative, revenue driving deals with other emerging brands, like we have done with Henry's Original, Pacific Remedy and Utopia. These deals are the first in an extensive pipeline of brand partnerships that we are now executing on. Investing in our partners enables them to scale and realize their aspirations while providing us with sizable upside and limited risk."

Mr. Hasan added, "We intend to leverage the foundation we have built in California to not just drive revenue growth, but also to grow and hone our employee base for deployment into new markets. The institutional knowledge we are developing from operating in the largest and most culturally significant cannabis market in the world has already taught us valuable lessons that we are carrying over to Canada. We are taking a calculated approach involving the use of a profitable and rapidly growing retail platform, 180 Smoke, for direct to consumer marketing by our brand partners. We are excited about this prospect, and are actively pursuing strategies for expansion of our brand partners into other regulated markets around the globe."

1) Internal source: based on rolling 6-month data 2) Includes the sale of: Anandia Laboratories Inc.; and Wagner Dimas Inc. (equity interest and license)

Financial Highlights – Q3 – 2018

The following are the major financial highlights of Origin House's operating results for the three months ended September 30, 2018, compared to the three months ended September 30, 2017:



revenues were $6.6 million as compared to $744,302 , an increase of 790%;





as compared to , an increase of 790%; gross margin was $298,619 as compared $128,010 , an increase of 133%;





as compared , an increase of 133%; operating expenses were $10.1 million as compared to $2.8 million , an increase of 261%;





as compared to , an increase of 261%; net loss of $7.5 million as compared to $3.3 million , an increase of 128%;





as compared to , an increase of 128%; net loss per basic and dilutive shares of $0.12 as compared to $0.08 ; and





as compared to ; and adjusted EBITDA loss of $4.5 million as compared to a loss of $1.8 million .

The following is a summary of key balance sheet totals as at September 30, 2018, compared to December 31, 2017.

cash was $75.3 million as compared to $4.5 million an increase of 1,565%;





as compared to an increase of 1,565%; total assets of $220.2 million as compared to $46.1 million , an increase of 377%;





as compared to , an increase of 377%; current assets of $90.8 million as compared to $7.9 million , an increase of 1,043%;





as compared to , an increase of 1,043%; current liabilities of $27.2 million as compared to $2.1 million , an increase of 1,172%; and





as compared to , an increase of 1,172%; and long-term debt of $28.2 million as compared to $2.3 million , an increase of 1,147%.



Recent Developments

For a more comprehensive overview of these recent developments, please refer to Origin House's Management's Discussion and Analysis of the Financial Condition and Results of Operations for the Three and Nine Months Ended September 30, 2018.

On October 3, 2018 , Origin House signed a definitive agreement with Australis whereby Australis will purchase 2,200,000 common shares in the capital of Wagner Dimas from Cannroy Delaware Inc. ("Cannroy Delaware"), a wholly-owned subsidiary of Origin House. The sale closed on November 19, 2018 .





, Origin House signed a definitive agreement with Australis whereby Australis will purchase 2,200,000 common shares in the capital of Wagner Dimas from Cannroy Delaware Inc. ("Cannroy Delaware"), a wholly-owned subsidiary of Origin House. The sale closed on . On October 3, 2018 , Trichome, entered into an agreement with 22 Capital to complete a transaction that will result in a reverse take-over of 22 Capital by the shareholders of Trichome. If completed, the resulting issuer will be listed on the TSX Venture Exchange.





, Trichome, entered into an agreement with 22 Capital to complete a transaction that will result in a reverse take-over of 22 Capital by the shareholders of Trichome. If completed, the resulting issuer will be listed on the TSX Venture Exchange. On October 18, 2018 , Origin House closed the previously announced acquisition of RVR Distribution ("RVR"). Upon closing the acquisition, Origin House gained legal control of RVR, however, the Company had control under IFRS 10 from September 1, 2018 . Additionally, Ted Simpkins , Co-Founder and CEO of RVR joined the Origin House Board of Directors, effective October 18, 2018 .





, Origin House closed the previously announced acquisition of RVR Distribution ("RVR"). Upon closing the acquisition, Origin House gained legal control of RVR, however, the Company had control under IFRS 10 from . Additionally, , Co-Founder and CEO of RVR joined the Origin House Board of Directors, effective . On October 22, 2018 , CannaRoyalty Corp. registered "Origin House" as a business name and began to conduct business under the Origin House brand.





, CannaRoyalty Corp. registered "Origin House" as a business name and began to conduct business under the Origin House brand. On October 23, 2018 , the Company's changed its ticker symbol from "CRZ" to "OH" on the Canadian Securities Exchange and from "CNNRF" to "ORHOF" on the OTCQX market in the United States .





, the Company's changed its ticker symbol from "CRZ" to "OH" on the Canadian Securities Exchange and from "CNNRF" to "ORHOF" on the OTCQX market in . On November 22, 2018 , Origin House began partnering with Mendocino Cannabis Brand, Henry's Original, to offer strategic investment and innovative brand acceleration.





, Origin House began partnering with Mendocino Cannabis Brand, Henry's Original, to offer strategic investment and innovative brand acceleration. On November 23, 2018 , the Company accelerated the expiry of all outstanding common share purchase warrants to December 14, 2018 . If all warrants are exercised they will generate proceeds of $10.6 million for Origin House.



Results of Operations (Summary)

The following tables set forth consolidated statements of financial information for the three and nine-month periods ending September 30, 2018, and September 30, 2017. For further information regarding the Company's financial results for these periods, please refer to the Company's Management's Discussion and Analysis for the periods ended September 30, 2018 and September 30, 2017 and the Company's Financial Statements for the periods ended September 30, 2018, published on Origin House's issuer profile on SEDAR at www.sedar.com and the Company's website at www.Origin House.com.











September 30,

2018 December 31,

2017 Change Selected statement of financial position data





Cash and cash equivalents $ 75,282,348 $ 4,522,644 $ 70,759,704 Working capital 63,658,301 5,813,705 57,844,596 Total investments (1) 10,874,921 26,674,288 (15,799,367) Total assets 220,204,036 46,139,757 174,064,279 Long term and convertible debt 28,171,149 2,258,467 25,912,682 Purchase consideration payable 2,136,274 - 2,136,274 Shareholders' equity 147,220,545 40,468,344 106,752,201 Dividends, per share - - -

(1) This represents the sum of investments, royalty investments, and interests in equity method









Three months ended September 30 Nine months ended September 30

2018 2017 2018 2017 Consolidated Statements of Net Loss







Revenue $ 6,623,998 $ 744,302 $ 10,778,901 $ 2,005,570 Gross margin, excluding fair value items 508,396 128,010 1,299,701 794,164 Operating expenses 10,064,130 2,834,939 20,824,360 8,629,385 Loss from operations (9,765,511) (2,706,929) (19,734,436) (7,835,221) Net loss (7,502,098) (3,295,477) (2,858,083) (7,816,773) Other income (expense) 2,015,184 (662,197) 16,737,179 (212,254) Total comprehensive loss (9,265,872) (3,618,961) (3,377,788) (8,677,392) Net loss per common share - basic & diluted (0.12) (0.08) (0.05) (0.19) Weighted average common shares - basic & diluted 57,621,347 42,156,344 51,634,188 40,961,436

Revenue by Type

Three months ended September 30 Nine months ended September 30

2018 2017 2018 2017 Product sales $ 6,250,992 $ 298,866 $ 9,446,382 $ 703,193 Services 69,760 41,451 737,921 314,594 Royalties 108,306 385,001 364,553 928,095 Interest income 194,940 18,984 230,045 59,688 Total $ 6,623,998 $ 744,302 $ 10,778,901 $ 2,005,570

Cost of Sales by Revenue Type

Three months ended September 30 Nine months ended September 30

2018 2017 2018 2017 Cost of product sales $ 5,900,572 $ 327,986 $ 8,354,623 $ 688,917 Cost of services 35,000 23,961 304,024 61,656 Cost of royalties 180,030 264,345 820,553 460,833 Total $ 6,115,602 $ 616,292 $ 9,479,200 $ 1,211,406

Gross Profit by Revenue Type

Three months ended September 30 Nine months ended September 30

2018 2017 2018 2017 Products $ 350,420 $ (29,120) $ 1,091,759 $ 14,276 Services 34,760 17,490 433,897 252,938 Royalties (71,724) 120,656 (456,000) 467,262 Interest 194,940 18,984 230,045 59,688 Total $ 508,396 $ 128,010 $ 1,299,701 $ 794,164

Gross Margin by Revenue Type

Three months ended September 30 Nine months ended September 30

2018 2017 2018 2017 Products 6% (10%) 12% 2% Services 50% 42% 59% 80% Royalties (66%) 31% (125%) 50% Interest 100% 100% 100% 100% All Types 8% 17% 12% 40%

Operating Expenses

Three months ended September 30

Nine months ended September 30



2018 2017 Change 2018 2017 Change Sales and marketing $ 1,947,706 $ 422,362 361% $ 3,535,796 $ 1,068,443 231% Research and product development 211,469 275,839 (23%) 472,371 900,932 (48%) General and administrative 6,457,990 1,943,675 232% 14,665,054 6,058,597 142% Amortization of intangibles 1,446,965 193,063 649% 2,151,139 601,413 258% Total $ 10,064,130 $ 2,834,939 255% $ 20,824,360 $ 8,629,385 141%

Adjusted EBITDA1

Three months ended September 30 Nine months ended September 30

2018 2017 2018 2017 Add (Subtract)







Net loss for the period $ (7,502,098) $ (3,295,477) $ (2,858,083) $ (7,816,773) Depreciation of property and equipment 174,274 46,532 300,072 137,730 Amortization of intangible assets 1,446,965 193,063 2,151,139 601,413 Amortization of royalty investments 180,030 245,753 820,553 411,145 Interest expense 1,185,257 85,935 1,846,540 122,054 Interest income (194,940) (18,984) (230,045) (59,688) Current income taxes 191,258 - 307,590 - Deferred income tax recovery (439,487) (73,649) (446,764) (230,702) EBITDA (4,958,741) (2,816,827) 1,891,002 (6,834,821) Listing expense - - - 38,193 Penalties from non-completion of transactions - (6,498) - 214,555 Gain on sale of equipment - (3,000) - (91,674) Gain on settlement of interests at acquisition (1,098,374) - (1,098,374) - Recovery on Achelois Inventory - - (441,370) - Share based compensation 1,143,050 695,144 4,222,563 2,499,356 Unrealized loss on embedded derivatives - 369,036 - 369,036 Realized fair value amounts included in

inventory sold 1,161,471 - 1,161,471 - Unrealized fair value gain on growth of

biological assets (951,694) - (951,694) - Transaction costs on acquisitions 254,714 - 536,840 - TOTAL ADJUSTED EBITDA $ (4,449,574) $ (1,762,145) $ 5,320,438 $ (4,937,462)

1 EBITDA and Adjusted EBITDA are non-GAAP financial measures and accordingly they are not earnings measures recognized by IFRS and do not carry standard prescribed significance. Moreover, our method for calculating Adjusted EBITDA may differ from that used by other companies using the same designation. Accordingly, we caution readers that Adjusted EBITDA should not be substituted for determining net income (loss) as an indicator of operating results or as a substitute for cash flows from operating and investing activities.

Share Capital

The Company's authorized share capital is an unlimited number of common shares of which 55,202,247 were issued and outstanding as at September 30, 2018 (December 31, 2017 – 43,898,445 common shares). The Company has issued 3,487,832 RSUs that have not been exercised as at September 30, 2018 including 2,357,837 that have vested (December 31, 2017 – 4,153,150 including 1,933,587 that had vested). As of September 30, 2018, there are share purchase warrants and broker warrants outstanding that can potentially be converted to 3,549,765 shares (December 31, 2017 – 4,112,712). The Company has issued 930,500 share options that have not been exercised as at September 30, 2018 including 270,750 that have vested (December 31, 2017 – 850,000 including 212,500 that had vested).

Conference Call

Origin House will host a conference call on, Wednesday, November 28, 2018 at 8:30 a.m. (Eastern Time) to discuss its 2018 third quarter financial results. The call will be chaired by Marc Lustig, Chief Executive Officer, Afzal Hasan, President and General Counsel and François Perrault, Chief Financial Officer.



Participant Dial-in Webcast Reference Number Conference Call 416-764-8688 or 1-888-390-0546 https://bit.ly/2FuLajf

Replay (available for 2 weeks) 416-764-8677 or 1-888-390-0541

543806

About Origin House

Origin House is a growing cannabis products and brands company operating across key markets in the U.S. and Canada, with a strategic focus on becoming a preeminent global house of cannabis brands. The Company's foundation is in California, the world's largest regulated cannabis market where it has delivered over 130 branded cannabis products to the majority of licensed dispensaries. Origin House's brand development platform is operated out of five licensed facilities located across California, and provides distribution, manufacturing, cultivation and marketing services for its brand partners. The Company is actively developing infrastructure to support the proliferation of its brands internationally, initially in Canada, through its pending acquisition of Canadian retailer 180 Smoke. Origin House's shares trade on the CSE under the symbol "OH" and on the OTCQX under the symbol "ORHOF". Origin House is the registered business name of Origin House Corp. For more information, visit www.originhouse.com.

Forward Looking Statements

Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in Origin House's periodic filings with Canadian securities regulators. When used in this news release, words such as "will, could, plan, estimate, expect, intend, may, potential, believe, should," and similar expressions, are forward- looking statements.

Forward-looking statements may include, without limitation, statements relating to timing for the Company's stock symbol change, the execution of the Company's strategy, including Phases I, II and III of the Company's business, the Company's timing and process for expansion in Canada and globally, timing for the Company's acquisition of 180 Smoke, new opportunities, future growth and other statements.

Although the Company has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; investing in target companies or projects that are engaged in activities currently considered illegal under US federal law; changes in laws; limited operating history; reliance on management; requirements for additional financing; competition; hindering market growth and state adoption due to inconsistent public opinion and perception of the medical-use and adult-use marijuana industry and; regulatory or political change.

There can be no assurance that such information will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.

Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. The Company disclaims any intention or obligation to update or revise such information, except as required by applicable law, and the Company does not assume any liability for disclosure relating to any other company mentioned herein.

Condensed Interim Consolidated Statements of Net Income (loss) (Unaudited)

In Canadian dollars







(UNAUDITED) Three months ended September 30 Nine months ended September 30 2018 2017 2018 2017









Revenue $ 6,623,998 $ 744,302 $ 10,778,901 $ 2,005,570









Cost of sales (6,115,602) (616,292) (9,479,200) (1,211,406)









Gross margin, excluding fair value items 508,396 128,010 1,299,701 794,164









Realized fair value amounts of inventory sold (1,161,471) - (1,161,471) - Unrealized fair value gain on growth of biological assets 951,694 - 951,694 - Gross margin 298,619 128,010 1,089,924 794,164









Operating expenses







Sales and marketing 1,947,706 422,362 3,535,796 1,068,443 Research and product development 211,469 275,839 472,371 900,932 General and administrative 6,457,990 1,943,675 14,665,054 6,058,597 Amortization of brands and technologies 1,446,965 193,063 2,151,139 601,413









Loss from operations (9,765,511) (2,706,929) (19,734,436) (7,835,221)









Other income (expenses)







Gain (loss) on investments (2,802,373) - 12,762,704 - Gain on the sale of licensed technology 4,196,477 - 4,196,477 - Fair value gain on warrants 104,344 - 104,344 - Recovery of convertible notes receivable 379,572 - 4,100 - Profit (loss) from equity accounted investees,

net of tax 10,106 (137,093) 168,664 706,821 Gain on settlement of interests at acquisition 1,098,374 - 1,098,374 - Foreign exchange gain (loss) 213,941 (79,631) 249,056 (266,911) Interest expense (1,185,257) (85,935) (1,846,540) (122,054) Penalties for non-completion of share swap transaction - 6,498 - (214,555) Unrealized loss on embedded derivatives - (369,036) - (369,036) Listing expense - - - (38,193) Gain on disposal of equipment - 3,000 - 91,674 Interest income - - - - Net loss before tax (7,750,327) (3,369,126) (2,997,257) (8,047,475)









Current tax expense (191,258) - (307,590) - Deferred tax recovery 439,487 73,649 446,764 230,702 Net loss for the period $ (7,502,098) $ (3,295,477) $ (2,858,083) $ (7,816,773)









Net loss per common share - basic & diluted (0.12) (0.08) (0.05) (0.19) Net loss per common share - diluted (0.13) (0.08) (0.05) (0.19)









Weighted average number of common shares outstanding - basic & diluted 57,621,347 42,156,344 51,634,188 40,961,436 Weighted average number of common shares outstanding - diluted 54,150,686 42,156,344 50,464,588 40,961,436









Total net loss for the period attributable to:







Owners of the company (7,179,771) (3,286,719) (2,608,647) (7,780,398) Attributable to non-controlling interest (322,327) (8,758) (249,436) (36,375)

$ (7,502,098) $ (3,295,477) $ (2,858,083) $ (7,816,773)

Condensed Interim Consolidated Statements of Financial Position (Unaudited)

In Canadian dollars









(UNAUDITED)

September 30,

2018 December 31,

2017







ASSETS





Current





Cash and cash equivalents

$ 75,282,348 $ 4,522,644 Amounts receivable

2,699,574 1,429,123 Inventory

7,380,045 270,169 Biological assets

698,766 - Prepaid and other assets

2,310,972 250,744 Advances and loans receivable - current

1,376,166 1,102,168 Asset held for sale

1,064,910 - Convertible notes

- 373,127



90,812,781 7,947,975







Non-Current





Deferred financing charges

1,561,852 - Advances and loans receivable

- 66,421 Interest in equity accounted investees

2,734,811 3,596,333 Investments

6,852,062 17,243,342 Royalty investments

1,288,048 5,834,613 Property and equipment

11,143,101 1,084,098 Intangible assets

49,920,100 5,607,598 Goodwill

55,891,281 4,759,377



129,391,255 38,191,782







Total Assets

$ 220,204,036 $ 46,139,757







LIABILITIES





Current





Amounts payable and accrued liabilities

$ 12,579,989 $ 1,606,689 Loans payable and other liabilities

13,184,582 425,345 Current tax liability

1,389,909 102,236



27,154,480 2,134,270







Non-Current





Capital lease

261,551 - Purchase consideration payable

2,136,274 - Convertible debt

27,909,598 1,431,950 Line of credit

- 826,517 Deferred tax liability

15,521,588 1,278,676 Total Liabilities

72,983,491 5,671,413







SHAREHOLDERS' EQUITY





Share capital

$ 105,823,518 $ 50,007,891 Share subscription and contingent shares

48,002,790 - Warrants reserve

4,590,904 4,149,703 Contributed surplus

15,280,457 9,902,292 Accumulated other comprehensive loss

(1,552,424) (1,032,719) Accumulated deficit

(25,099,602) (22,381,817) Non-controlling interest

174,902 (177,006) Shareholders' Equity

147,220,545 40,468,344







Total Liabilities & Shareholders' Equity

$ 220,204,036 $ 46,139,757

Condensed Interim Consolidated Statements of Cash Flows (Unaudited)

In Canadian dollars





(UNAUDITED) Nine months ended September 30 2018 2017





CASH FLOWS USED IN OPERATING ACTIVITIES



Net income (loss) for the period $ (2,858,083) $ (7,816,773) Items not affecting cash:



Bad debt expense (recovery) 33,122 (7,268) Income from equity accounted investees (168,664) (706,821) Amortization of property and equipment 300,072 137,730 Amortization of intangibles 2,151,139 601,413 Amortization of royalties 820,553 411,145 Amortization of fees related to line of credit 611,631 68,469 Share based compensation 4,222,561 2,499,356 Consulting fees paid via issuance of shares - 30,000 Transaction adjustment paid via issuance of shares - 204,060 Deferred tax recovery (446,764) (230,702) Recovery on impairment of convertible notes receivable (4,100) - Loss related to change in fair value of embedded derivatives - 369,036 Write-off of inventory, net of recoveries 12,267 - Accretion of convertible debt 378,292 - Gain on reclassification of assets held for sale - - Gain on disposal of equipment - (91,674) Realized fair value amounts of inventory sold 1,161,471 - Unrealized fair value gain on growth of biological assets (951,694) - Gain on settlement of interests at acquisition (1,098,374) - Fair value gain on warrants (104,344) - Gain on the sale of licensed technology (4,196,477) - Gains on investments (12,762,704) -

(12,900,096) (4,532,029) Changes in non-cash items relating to operations:



Increase in amounts receivable (123,412) (1,064,247) Increase in inventory (1,860,749) (147,211) Increase in prepaid and other assets (1,224,839) (156,794) Increase (decrease) in accounts payable and accruals 1,863,400 (1,021,754) Increase in biological assets (259,917) - Increase in current tax liability 251,968 -

(14,253,645) (6,922,035)





CASH FLOWS FROM/(USED) IN INVESTING ACTIVITIES



Purchase of property and equipment (6,811,821) (151,861) Purchase of Intangible assets (54,924) - Payments for acquisitions, net of cash received (1,074,056) - Proceeds from the sale of investments 28,139,404 - Proceeds from the collection of convertible debt 392,100 - Purchase of interests in equity accounted investments - (1,917,884) Royalty financing arrangements (1,265,000) (3,962,131) Loans advanced to debtors including issuance costs, net of repayment (2,848,359) (1,488,018)

16,477,344 (7,519,894)





CASH FLOWS FROM FINANCING ACTIVITIES



Proceeds from issued shares in bought deal financing, net of costs 12,015,990 10,958,243 Proceeds from issuance of convertible debt, net of costs 31,249,904 - Proceeds from issuance of warrants, net of costs 3,628,950 2,787,000 Proceeds from exercise of warrants 11,665,043 404,592 Repayment of line of credit (3,000,000) - Rapayment of loans (71,467) - Proceeds from common and preferred shares issued to minority holders of Trichome 13,259,530 - Proceeds from issuance of stock options 186,500 25,000 Payments related to share buyback bid (98,382) - Tax withholding paid on exercise of restricted share units - (84,887)

68,836,068 14,089,948 Effect of movement of exchange rates on cash held (300,063) -





INCREASE (DECREASE) IN CASH $ 70,759,704 $ (351,981)





CASH, BEGINNING OF PERIOD 4,522,644 2,945,895





CASH, END OF PERIOD $ 75,282,348 $ 2,593,914

SOURCE Origin House

For further information: Marc Lustig, Chairman and CEO, [email protected], 1-844-556-5070, www.originhouse.com; Jonathan Ross, CFA, LodeRock Advisors Inc., [email protected], 416-283-0178